Stuart J Knechtle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3173592/publications.pdf

Version: 2024-02-01

311 papers

16,669 citations

66 h-index

14614

117 g-index

463 all docs

463 docs citations

463 times ranked

10973 citing authors

#	Article	IF	CITATIONS
1	Letter to the editor in response to: Measuring success in pig to non-human-primate renal xenotransplantation: Systematic review and comparative outcomes analysis of 1051 life sustaining NHP renal allo- and xeno-transplants by Firl and Markmann. American Journal of Transplantation, 2022, 22, 1933-1934.	2.6	1
2	Introducing thymus for promoting transplantation tolerance. Journal of Allergy and Clinical Immunology, 2022, 150, 549-556.	1.5	5
3	Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney International, 2021, 99, 161-172.	2.6	27
4	Definition and Analysis of Textbook Outcome: A Novel Quality Measure in Kidney Transplantation. World Journal of Surgery, 2021, 45, 1504-1513.	0.8	12
5	Pointâ€ofâ€Care Assessment of DCD Livers During Normothermic Machine Perfusion in a Nonhuman Primate Model. Hepatology Communications, 2021, 5, 1527-1542.	2.0	7
6	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology, 2021, 12, 694763.	2.2	16
7	Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. Frontiers in Immunology, 2021, 12, 660900.	2.2	7
8	Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells. Frontiers in Immunology, 2021, 12, 705140.	2.2	4
9	Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. Journal of Clinical Medicine, 2021, 10, 3656.	1.0	5
10	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
11	Optical coherence tomography of small intestine allograft biopsies using a handheld surgical probe. Journal of Biomedical Optics, 2021, 26, .	1.4	4
12	Another Step Toward Becoming a Transplant Community. Annals of Surgery, 2021, 273, e149-e150.	2.1	0
13	A Historical Cohort in Kidney Transplantation: 55-Year Follow-Up of 72 HLA-Identical, Donor-Recipient Pairs. Journal of Clinical Medicine, 2021, 10, 5505.	1.0	1
14	A cell-based multiplex immunoassay platform using fluorescent protein-barcoded reporter cell lines. Communications Biology, 2021, 4, 1338.	2.0	6
15	B cells in transplant tolerance and rejection: friends or foes?. Transplant International, 2020, 33, 30-40.	0.8	36
16	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
17	Percutaneous Splenorenal Shunt Creation in a Patient with Chronic Portomesenteric Thrombosis. Journal of Vascular and Interventional Radiology, 2020, 31, 1408-1409.	0.2	2
18	Outcomes in Kidney Transplantation Between Veterans Affairs and Civilian Hospitals. Annals of Surgery, 2020, 272, 506-510.	2.1	5

#	Article	IF	Citations
19	Pharmacological approaches to antibody-mediated rejection—Are we getting closer?. American Journal of Transplantation, 2020, 20, 2637-2638.	2.6	2
20	Experimental modeling of desensitization: What have we learned about preventing AMR?. American Journal of Transplantation, 2020, 20, 2-11.	2.6	12
21	Textbook Outcomes in Liver Transplantation. World Journal of Surgery, 2020, 44, 3470-3477.	0.8	40
22	Targeting Calcium Release–activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. Transplantation, 2020, 104, 970-980.	0.5	0
23	Donor apoptotic cell–based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients. American Journal of Transplantation, 2020, 20, 2728-2739.	2.6	9
24	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	6.3	266
25	Antibody-Mediated Graft Rejection in Nonhuman Primate Models: Comparison of Sensitized Allotransplant and Xenotransplant Rejection. , 2020, , 157-164.		1
26	Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy. American Journal of Gastroenterology, 2020, 115, 1935-1935.	0.2	0
27	Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. American Journal of Transplantation, 2019, 19, 724-736.	2.6	61
28	Translational impact of NIH-funded nonhuman primate research in transplantation. Science Translational Medicine, 2019, 11 , .	5.8	27
29	Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0220527.	1.1	46
30	The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. Journal of the American Geriatrics Society, 2019, 67, 794-798.	1.3	43
31	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. Journal of the American Society of Nephrology: JASN, 2019, 30, 1206-1219.	3.0	85
32	A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?. Transplantation, 2019, 103, 1675-1682.	0.5	10
33	Improvement in Liver Transplant Outcomes From Older Donors. Annals of Surgery, 2019, 270, 333-339.	2.1	36
34	Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation. Transplantation Reviews, 2019, 33, 115-129.	1.2	10
35	Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2019, 30, 2399-2411.	3.0	51
36	The past, present, and future of costimulation blockade in organ transplantation. Current Opinion in Organ Transplantation, 2019, 24, 391-401.	0.8	36

#	Article	IF	Citations
37	Early Course of the Patient With a Kidney Transplant. , 2019, , 198-211.		1
38	Results of Renal Transplantation. , 2019, , 684-708.		2
39	Toward Long-term Livers. Annals of Surgery, 2019, 269, 28-29.	2.1	0
40	Parallels between antibody-mediated rejection and ischemic kidney injury with respect to B cell activation. Annals of Translational Medicine, 2019, 7, S151-S151.	0.7	1
41	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	2.6	205
42	Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. Transplantation Reviews, 2018, 32, 119-126.	1.2	12
43	The Volume-outcome Relationship in Deceased Donor Kidney Transplantation and Implications for Regionalization. Annals of Surgery, 2018, 267, 1169-1172.	2.1	18
44	Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes. Transplantation Direct, 2018, 4, e349.	0.8	20
45	Identification and Management of Abdominal Wall Varices in Pregnancy. Obstetrics and Gynecology, 2018, 132, 882-887.	1.2	6
46	IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade. Frontiers in Immunology, 2018, 9, 2323.	2.2	7
47	Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. Pediatric Transplantation, 2018, 22, e13305.	0.5	27
48	Contemporary Strategies and Barriers to Transplantation Tolerance. Transplantation, 2018, 102, 1213-1222.	0.5	23
49	Improved survival in simultaneous lung-liver recipients and candidates in the modern era of lung allocation. Journal of Surgical Research, 2018, 231, 395-402.	0.8	9
50	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. Clinical Transplantation, 2018, 32, e13388.	0.8	6
51	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 410-420.	0.9	13
52	Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. American Journal of Transplantation, 2017, 17, 2055-2064.	2.6	14
53	Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 1991-1996.	3.0	67
54	Crosstalk Between T and B Cells in the Germinal Center After Transplantation. Transplantation, 2017, 101, 704-712.	0.5	51

#	Article	IF	Citations
55	Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplantation Direct, 2017, 3, e206.	0.8	9
56	Elevated HbA1c in donor organs from patients without a diagnosis of diabetes portends worse liver allograft survival. Clinical Transplantation, 2017, 31, e13047.	0.8	1
57	Hypoxia of the growing liver accelerates regeneration. Surgery, 2017, 161, 666-679.	1.0	73
58	Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Advances, 2017, 1, 2115-2119.	2.5	39
59	Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Frontiers in Immunology, 2017, 8, 1615.	2.2	4
60	Portal hypertensive bleeding., 2017,, 1218-1230.e3.		0
61	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. American Journal of Transplantation, 2016, 16, 2816-2835.	2.6	451
62	Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. American Journal of Transplantation, 2016, 16, 1726-1738.	2.6	37
63	One Size Does Not Fit Allâ€"Regional Variation in the Impact of the Share 35 Liver Allocation Policy. American Journal of Transplantation, 2016, 16, 137-142.	2.6	34
64	Reply to: "Percutaneous Management of Benign Biliary Strictures: Is It Time to Focus on Reducing Procedure Invasiveness?". Journal of Vascular and Interventional Radiology, 2016, 27, 936-937.	0.2	0
65	Expanding the Donor Pool With Normothermic Ex Vivo Liver Perfusion: The Future Is Now. American Journal of Transplantation, 2016, 16, 3075-3076.	2.6	13
66	Regulating T Cell Behavior. American Journal of Transplantation, 2016, 16, 1949-1950.	2.6	2
67	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. American Journal of Transplantation, 2016, 16, 2612-2623.	2.6	18
68	Percutaneous Management of Benign Biliary Strictures with Large-Bore Catheters: Comparison between Patients with and without Orthotopic Liver Transplantation. Journal of Vascular and Interventional Radiology, 2016, 27, 219-225.e1.	0.2	25
69	Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. Journal of the American Society of Nephrology: JASN, 2016, 27, 626-636.	3.0	58
70	Surgical Technique in Transplantation: How Much Does It Matter?. American Journal of Transplantation, 2015, 15, 2791-2792.	2.6	3
71	The Association Between Hospital Finances and Complications After Complex Abdominal Surgery. Annals of Surgery, 2015, 262, 273-279.	2.1	31
72	Longitudinal Studies of a B Cell–Derived Signature of Tolerance in Renal Transplant Recipients. American Journal of Transplantation, 2015, 15, 2908-2920.	2.6	87

#	Article	IF	Citations
73	Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. Transplantation, 2015, 99, 2485-2493.	0.5	13
74	Openâ€label prospective study of the safety and efficacy of glassâ€based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer, 2015, 121, 2164-2174.	2.0	51
75	Equalizing MELD Scores Over Broad Geographies Is Not the Most Efficacious Way to Allocate a Scarce Resource in a Value-based Environment. Annals of Surgery, 2015, 262, 220-223.	2.1	8
76	Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model. American Journal of Transplantation, 2015, 15, 815-822.	2.6	56
77	Systems biological analyses reveal the hepatitis C virus (HCV)â€specific regulation of hematopoietic development. Hepatology, 2015, 61, 843-856.	3.6	6
78	Belatacept: Is There BENEFIT for Liver Transplantation Too?. American Journal of Transplantation, 2014, 14, 1717-1718.	2.6	11
79	Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. Liver Transplantation, 2014, 20, 100-115.	1.3	51
80	Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody-Mediated Rejection. American Journal of Transplantation, 2014, 14, 59-69.	2.6	157
81	Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. Journal of Surgical Oncology, 2014, 109, 533-541.	0.8	22
82	The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. American Journal of Transplantation, 2014, 14, 779-787.	2.6	182
83	Urine proteomics in kidney transplantation. Transplantation Reviews, 2014, 28, 15-20.	1.2	35
84	An Introduction to Pediatric Organ Transplantation. , 2014, , 1353-1356.		0
85	Transplant Clinic Management. , 2014, , 1518-1532.		0
86	Abdominal Solid Organ Transplantation Fellowship Training. , 2014, , 1562-1565.		0
87	Medical Solid Organ Transplant Fellowship Training. , 2014, , 1566-1571.		0
88	Laparoscopic vs Open Right Hepatectomy: A Value-Based Analysis. Journal of the American College of Surgeons, 2014, 218, 929-939.	0.2	58
89	Administration of Organ Procurement and Allocation. , 2014, , 251-263.		0
90	Results of Renal Transplantation. , 2014, , 676-697.		1

#	Article	IF	CITATIONS
91	Preface to the Seventh Edition. , 2014, , xi.		0
92	Early Course of the Patient withÂaÂKidney Transplant. , 2014, , 204-215.		0
93	Domino Liver Transplantation in Maple Syrup Urine Disease: A Case Report and Review of the Literature. Transplantation Proceedings, 2013, 45, 806-809.	0.3	27
94	Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). Experimental and Toxicologic Pathology, 2013, 65, 1019-1024.	2.1	8
95	Reply to Vanhove <i>etÂal</i> . Transplant International, 2013, 26, e26-e27.	0.8	0
96	Induction immunosuppression in liver transplantation: a review. Transplant International, 2013, 26, 673-683.	0.8	63
97	Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts. New England Journal of Medicine, 2013, 369, 20-31.	13.9	312
98	Lymphodepletional Strategies in Transplantation. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015511-a015511.	2.9	24
99	Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology, 2013, 57, 708-715.	3.6	88
100	Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transplant International, 2013, 26, 592-600.	0.8	24
101	Starting Well: Induction Immunosuppression after Organ Transplantation. Transplant International, 2013, 26, 661-661.	0.8	0
102	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013, 174, 364-371.	1.1	41
103	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. PLoS ONE, 2013, 8, e74225.	1.1	49
104	Humoral Immunity Induced By Viral Infection Provides a Major Barrier To Hematopoietic Cell Transplantation. Blood, 2013, 122, 894-894.	0.6	1
105	Tolerogenic therapies in transplantation. Frontiers in Immunology, 2012, 3, 198.	2.2	58
106	Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology, 2012, 56, 2071-2081.	3.6	34
107	The role of B cells in solid organ transplantation. Seminars in Immunology, 2012, 24, 96-108.	2.7	35
108	The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis. American Journal of Pathology, 2012, 181, 1693-1701.	1.9	48

#	Article	IF	CITATIONS
109	Enhanced De Novo Alloantibody and Antibody-Mediated Injury in Rhesus Macaques. American Journal of Transplantation, 2012, 12, 2395-2405.	2.6	24
110	Patterns of De Novo Allo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment. American Journal of Transplantation, 2012, 12, 2641-2651.	2.6	29
111	Biologics in organ transplantation. Transplant International, 2012, 25, 707-719.	0.8	26
112	Location of portosystemic shunting. , 2012, , 1146-1158.e3.		0
113	Seek and You Will Find: Antibody and the Liver. American Journal of Transplantation, 2011, 11, 424-425.	2.6	4
114	Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney Transplants. American Journal of Transplantation, 2011, 11, 841-847.	2.6	92
115	Guidance for Liver Transplant Immunosuppression. American Journal of Transplantation, 2011, 11, 886-887.	2.6	3
116	Miles to Go…. American Journal of Transplantation, 2011, 11, 1119-1120.	2.6	16
117	Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-enhanced MR Imaging—Comparison to Prior Same-Center Results after MR Systems Improvements. Radiology, 2011, 261, 824-833.	3.6	51
118	Primary Vascularization of the Graft Determines the Immunodominance of Murine Minor H Antigens during Organ Transplantation. Journal of Immunology, 2011, 187, 3997-4006.	0.4	17
119	Interleukin-15 Receptor Blockade in Non-Human Primate Kidney Transplantation. Transplantation, 2010, 89, 937-944.	0.5	11
120	Cytokine kinetics profiling in pediatric renal transplant recipients. Pediatric Transplantation, 2010, 14, 636-645.	0.5	0
121	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.4	18
122	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1197-1204.	0.2	16
123	Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagnostic Microbiology and Infectious Disease, 2010, 66, 7-15.	0.8	42
124	Immunoregulation and Tolerance. Transplantation Proceedings, 2010, 42, S13-S15.	0.3	12
125	Prevention trumps treatment of antibody-mediated transplant rejection. Journal of Clinical Investigation, 2010, 120, 1036-1039.	3.9	5
126	Unique Aspects of Rejection and Tolerance in Liver Transplantation. Seminars in Liver Disease, 2009, 29, 091-101.	1.8	73

#	Article	IF	CITATIONS
127	Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. Journal of Rheumatology, 2009, 36, 2224-2230.	1.0	59
128	Early and Limited Use of Tacrolimus to Avoid Rejection in an Alemtuzumab and Sirolimus Regimen for Kidney Transplantation: Clinical Results and Immune Monitoring. American Journal of Transplantation, 2009, 9, 1087-1098.	2.6	67
129	BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab. American Journal of Transplantation, 2009, 9, 1835-1845.	2.6	88
130	HLA-C and Liver Transplant Outcomes: Interpreting the Facts. American Journal of Transplantation, 2009, 9, 1491-1492.	2.6	3
131	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. Transplantation, 2009, 87, 125-132.	0.5	46
132	Overcoming Chronic Rejectionâ€"Can it B?. Transplantation, 2009, 88, 955-961.	0.5	37
133	Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine. Transplantation, 2009, 87, 1814-1820.	0.5	77
134	Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. Liver Transplantation, 2008, 14, 1461-1465.	1.3	38
135	Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transplant International, 2008, 21, 625-636.	0.8	34
136	Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatric Transplantation, 2008, 12, 447-455.	0.5	34
137	CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H. American Journal of Transplantation, 2008, 8, 793-802.	2.6	158
138	Unaltered Graft Survival and Intragraft Lymphocytes Infiltration in the Cardiac Allograft of Cxcr3â^'/â^' Mouse Recipients. American Journal of Transplantation, 2008, 8, 1593-1603.	2.6	34
139	Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells. American Journal of Transplantation, 2008, 8, 1529-1536.	2.6	69
140	A Comparison of Alemtuzumab with Basiliximab Induction in Simultaneous Pancreas–Kidney Transplantation. American Journal of Transplantation, 2008, 8, 1702-1710.	2.6	43
141	Surgical invention and commercialization. Surgery, 2008, 143, 175-181.	1.0	2
142	The Impact of Donor Variables on the Outcome of Orthotopic Liver Transplantation for Hepatitis C. Transplantation Proceedings, 2008, 40, 219-223.	0.3	31
143	Macrophages Driven to a Novel State of Activation Have Anti-Inflammatory Properties in Mice. Journal of Immunology, 2008, 180, 335-349.	0.4	80
144	Nonhuman Primate Infections after Organ Transplantation. ILAR Journal, 2008, 49, 209-219.	1.8	33

#	Article	IF	Citations
145	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2008, 19, 812-824.	3.0	28
146	Early Course of the Patient with a Kidney Transplant. , 2008, , 210-219.		2
147	Results of Renal Transplantation. , 2008, , 657-675.		2
148	Vascular Access for Dialysis, Chemotherapy, and Nutritional Support., 2008, , 1457-1468.		0
149	Developmental Exposure to Noninherited Maternal Antigens Induces CD4+T Regulatory Cells: Relevance to Mechanism of Heart Allograft Tolerance. Journal of Immunology, 2007, 179, 6749-6761.	0.4	59
150	Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3â^'/â^' Mouse Recipients. Journal of Immunology, 2007, 179, 8016-8025.	0.4	18
151	Human CD4+CD25low Adaptive T Regulatory Cells Suppress Delayed-Type Hypersensitivity during Transplant Tolerance. Journal of Immunology, 2007, 178, 3983-3995.	0.4	58
152	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. Transplantation, 2007, 83, 1429-1434.	0.5	35
153	Liver transplantation 2007: where do we go from here?. Current Opinion in Organ Transplantation, 2007, 12, 211-214.	0.8	0
154	Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. Pediatric Transplantation, 2007, 11, 661-670.	0.5	59
155	CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology, 2007, 120, 467-485.	2.0	45
156	Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab. American Journal of Transplantation, 2007, 7, 2619-2625.	2.6	194
157	Review: chemokines in transplantation. Transplantation Reviews, 2007, 21, 107-118.	1.2	3
158	Immunosuppression in nonhuman primates. Transplantation Reviews, 2006, 20, 131-138.	1.2	1
159	Determination of the Functional Status of Alloreactive T Cells by Interferon-?? Kinetics. Transplantation, 2006, 81, 590-598.	0.5	16
160	T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients. Transplantation, 2006, 81, 81-87.	0.5	83
161	The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant International, 2006, 19, 705-714.	0.8	131
162	Outcomes at 3â€fyears of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transplant International, 2006, 19, 885-892.	0.8	66

#	Article	IF	Citations
163	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation, 2006, 6, 876-883.	2.6	135
164	Elevation of multiple cytokines/chemokines in urine of human renal transplant recipients with acute and chronic injuries: potential usage for diagnosis and monitoring. Transplantation Reviews, 2006, 20, 165-171.	1.2	5
165	Donation After Cardiac Death. Annals of Surgery, 2005, 242, 724-731.	2.1	342
166	Simultaneous Pancreas-Kidney Transplantation From Donation After Cardiac Death. Annals of Surgery, 2005, 242, 716-723.	2.1	89
167	Selenium-Binding Protein-1 in Smooth Muscle Cells is Downregulated in a Rhesus Monkey Model of Chronic Allograft Nephropathy. American Journal of Transplantation, 2005, 5, 58-67.	2.6	14
168	Campath-1H Use in Pediatric Renal Transplantation. American Journal of Transplantation, 2005, 5, 1569-1573.	2.6	85
169	Liver transplantation for HELLP syndrome. Liver Transplantation, 2005, 11, 224-228.	1.3	85
170	Development of tolerogenic strategies in the clinic. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1739-1746.	1.8	14
171	How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?. Nature Clinical Practice Nephrology, 2005, 1, 74-75.	2.0	1
172	Incidental living donor nephrectomy: a unique expansion of the donor pool. Nephrology Dialysis Transplantation, 2005, 20, 245-246.	0.4	0
173	Infected Bilomas in Liver Transplant Recipients: Clinical Features, Optimal Management, and Risk Factors for Mortality. Clinical Infectious Diseases, 2004, 39, 517-525.	2.9	46
174	Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF-Î ² 1+CD4+T Regulatory Cell Infiltrates. Journal of Immunology, 2004, 172, 5753-5764.	0.4	76
175	Elevation of CXCR3-Binding Chemokines in Urine Indicates Acute Renal-Allograft Dysfunction. American Journal of Transplantation, 2004, 4, 432-437.	2.6	156
176	Infected Bilomas in Liver Transplant Recipients, Incidence, Risk Factors and Implications for Prevention. American Journal of Transplantation, 2004, 4, 574-582.	2.6	71
177	Donation After Cardiac Death: The University of Wisconsin Experience with Renal Transplantation. American Journal of Transplantation, 2004, 4, 1490-1494.	2.6	152
178	Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery, 2004, 136, 754-760.	1.0	139
179	Superior Long-Term Results of Simultaneous Pancreas-Kidney Transplantation from Pediatric Donors. American Journal of Transplantation, 2004, 4, 2093-2101.	2.6	49
180	Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatric Transplantation, 2004, 8, 106-112.	0.5	41

#	Article	IF	CITATIONS
181	Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. Transplant Immunology, 2004, 13, 147-154.	0.6	3
182	Surveillance of Acute Rejection in Baboon Renal Transplantation by Elevation of Interferon-Î ³ Inducible Protein-10 and Monokine Induced by Interferon-Î ³ in Urine. Transplantation, 2004, 78, 1002-1007.	0.5	33
183	Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model1. Transplantation, 2004, 77, 914-920.	0.5	74
184	Metastable tolerance in nonhuman primates and humans. Transplantation, 2004, 77, 936-939.	0.5	30
185	Challenging Choices. Annals of Surgery, 2004, 239, 160-161.	2.1	2
186	Correlation Between Human Leukocyte Antigen Antibody Production and Serum Creatinine in Patients Receiving Sirolimus Monotherapy after Campath-1H Induction. Transplantation, 2004, 78, 919-924.	0.5	47
187	Hepatic steatosis and liver transplantation. Current Opinion in Organ Transplantation, 2004, 9, 123-129.	0.8	3
188	Clinical trials: where are we now?. Immunological Reviews, 2003, 196, 237-246.	2.8	5
189	Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. American Journal of Transplantation, 2003, 3, 722-730.	2.6	360
190	Alemtuzumab and tolerance: the university of wisconsin experience. Transplantation Reviews, 2003, 17, S26-S28.	1.2	0
191	Involvement of linker for activation of T cells in the costimulatory signaling pathways. Transplantation Proceedings, 2003, 35, 553-554.	0.3	0
192	An overview of the actions of cyclosporine and FK506. Transplantation Reviews, 2003, 17, 165-171.	1.2	11
193	Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. International Immunology, 2003, 15, 1369-1378.	1.8	10
194	Underutilization of pancreas donors. Transplantation, 2003, 75, 1271-1276.	0.5	103
195	Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection1. Transplantation, 2003, 76, 524-530.	0.5	37
196	Mycophenolate mofetil: what is the evidence that it decreases chronic rejection?. Current Opinion in Organ Transplantation, 2003, 8, 313-316.	0.8	0
197	Novel agents or strategies for immunosuppression after renal transplantation. Current Opinion in Organ Transplantation, 2003, 8, 172-178.	0.8	2
198	Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling1. Transplantation, 2003, 75, 1075-1077.	0.5	13

#	Article	IF	Citations
199	Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical livingrelated, and living-unrelated grafts1. Transplantation, 2003, 75, 1677-1682.	0.5	51
200	From Eck's Fistula to TIPS. Annals of Surgery, 2003, 238, S49-S55.	2.1	6
201	Kidney Transplantation and Dialysis Access. , 2003, , 607-615.		0
202	Long-term outcomes in simultaneous pancreas-kidney transplantation: lessons relearned. Clinical Transplants, 2003, , 215-20.	0.2	1
203	Prolongation of Long-Term Kidney Graft Survival by a Simultaneous Liver Transplant: The Liver Does It, and the Heart Does It Too Transplantation, 2002, 74, 1370-1371.	0.5	3
204	Piceatannol in combination with low doses of cyclosporine a prolongs kidney allograft survival in a stringent rat transplantation model 1, 2. Transplantation, 2002, 74, 1609-1617.	0.5	12
205	Steps toward transplantation tolerance in the clinic. Transplantation Proceedings, 2001, 33, 3844-3845.	0.3	1
206	Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 2001, 5, 594-602.	0.9	27
207	Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunological Reviews, 2001, 183, 205-213.	2.8	41
208	What's new in transplantation. Journal of the American College of Surgeons, 2001, 192, 366-371.	0.2	1
209	Treatment with immunotoxin. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 681-689.	1.8	32
210	STUDIES OF PEDIATRIC LIVER TRANSPLANTATION (SPLIT): YEAR 2000 OUTCOMES. Transplantation, 2001, 72, 463-476.	0.5	119
211	IMMUNOTOXIN FN18-CRM9 INDUCES STRONGER T CELL SIGNALING THAN UNCONJUGATED MONOCLONAL ANTIBODY FN1812. Transplantation, 2001, 72, 496-503.	0.5	6
212	GRAFT SURVIVAL IN A RHESUS RENAL TRANSPLANT MODEL AFTER IMMUNOTOXIN-MEDIATED T-CELL DEPLETION IS ENHANCED BY MYCOPHENOLATE AND STEROIDS1,2. Transplantation, 2001, 72, 581-587.	0.5	9
213	SUCCESSFUL CONVERSION FROM CONVENTIONAL IMMUNOSUPPRESSION TO ANTI-CD154 MONOCLONAL ANTIBODY COSTIMULATORY MOLECULE BLOCKADE IN RHESUS RENAL ALLOGRAFT RECIPIENTS1,2. Transplantation, 2001, 72, 587-597.	0.5	38
214	Kidney Transplantation and Dialysis Access. , 2001, , 1449-1462.		0
215	Costimulatory Blockade as a Therapeutic Regimen for Prolonging Allograft Survival and Inducing Tolerance: An Overview of Recent Research., 2001,, 127-158.		О
216	Tolerance induction., 2001,, 149-168.		0

#	Article	IF	Citations
217	Simultaneous Pancreas–Kidney (SPK) Transplantation from Controlled Non-Heart-Beating Donors (NHBDs). Cell Transplantation, 2000, 9, 889-893.	1.2	49
218	DETECTION OF CELLS RECOGNIZING DONOR GRAFTDERIVED FIBROBLASTS IN THE BLOOD OF ALLOGRAFTREJECTING ANIMALS Transplantation, 2000, 69, S152.	0.5	1
219	EARLY RESULTS IN THE USE OF THYMOGLOBULIN AND SIMULECT AS INDUCTION THERAPY IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS Transplantation, 2000, 69, S160.	0.5	O
220	CD40:CD154 interactions and allograft rejection. Current Opinion in Organ Transplantation, 2000, 5, 10-15.	0.8	10
221	IMMUNOREGULATION IN MONKEY KIDNEY ALLOGRAFT ACCEPTANCE: BYSTANDER SUPPRESSION OF DTH TRIGGERED BY DONOR ANTIGENS Transplantation, 2000, 69, S242.	0.5	1
222	LONG-TERM RESULTS OF LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER12. Transplantation, 2000, 70, 780-783.	0.5	117
223	T-cell depletion as a means of achieving tolerance. Current Opinion in Organ Transplantation, 2000, 5, 96-102.	0.8	7
224	Simultaneous Pancreas-Kidney Transplantation and Living Related Donor Renal Transplantation in Patients With Diabetes: Is There a Difference in Survival?. Annals of Surgery, 2000, 231, 417-423.	2.1	122
225	Knowledge about transplantation tolerance gained in primates. Current Opinion in Immunology, 2000, 12, 552-556.	2.4	36
226	Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. Blood, 2000, 95, 2733-2741.	0.6	13
227	Regulation of T Cell Receptor- and CD28-induced Tyrosine Phosphorylation of the Focal Adhesion Tyrosine Kinases Pyk2 and Fak by Protein Kinase C. Journal of Biological Chemistry, 2000, 275, 1344-1350.	1.6	14
228	Liver transplantation from controlled non-heart–beating donors. Surgery, 2000, 128, 579-588.	1.0	177
229	INCREASED GLOMERULAR DEPOSITS OF VON WILLEBRAND FACTOR IN CHRONIC, BUT NOT ACUTE, REJECTION OF PRIMATE RENAL ALLOGRAFTS1. Transplantation, 2000, 70, 877-886.	0.5	10
230	CD28 Ligation Induces Tyrosine Phosphorylation of Pyk2 but Not Fak in Jurkat T Cells. Journal of Biological Chemistry, 1999, 274, 6735-6740.	1.6	31
231	Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. Clinical Transplantation, 1999, 13, 349-355.	0.8	69
232	Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Medicine, 1999, 5, 686-693.	15.2	801
233	Ureteroneocystostomy for renal transplantation. Journal of the American College of Surgeons, 1999, 188, 707-709.	0.2	19
234	CD28 ligation induces rapid tyrosine phosphorylation of the linker molecule LAT in the absence of Syk and ZAP-70 tyrosine phosphorylation. European Journal of Immunology, 1999, 29, 2354-2359.	1.6	25

#	Article	IF	CITATIONS
235	Surgical portosystemic shunts for treatment of portal hypertensive bleeding: Outcome and effect on liver function. Surgery, 1999, 126, 708-713.	1.0	28
236	Utilization of pediatric donors for pancreas transplantation. Transplantation Proceedings, 1999, 31, 610-611.	0.3	28
237	Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. Transplantation Proceedings, 1999, 31, 785.	0.3	3
238	ILIAC ARTERY PSEUDOANEURYSM FOLLOWING RENAL TRANSPLANTATION PRESENTING AS LUMBOSACRAL PLEXOPATHY. Transplantation, 1999, 67, 1077-1078.	0.5	45
239	THE IMPACT OF HYPOALBUMINEMIA IN KIDNEY-PANCREAS TRANSPLANT RECIPIENTS 1. Transplantation, 1999, 68, 72-75.	0.5	35
240	ACTIVATION OF T LYMPHOCYTES FOR ADHESION AND CYTOKINE EXPRESSION BY TOXIN-CONJUGATED ANTI-CD3 MONOCLONAL ANTIBODIES1. Transplantation, 1999, 68, 693-698.	0.5	11
241	ANALYSIS OF REJECTION AND ATN AFTER INDUCTION WITH ATG, BASILIXIMAB AND DACLIZIMAB IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, S546.	0.5	3
242	Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. Liver Transplantation, 1998, 4, 483-490.	1.9	39
243	Strategies for tolerance induction in nonhuman primates. Current Opinion in Immunology, 1998, 10, 513-517.	2.4	35
244	Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. Human Immunology, 1998, 59, 415-425.	1.2	20
245	Two distinct forms of soluble MHC class I molecules synthesized by different mechanisms in normal rat cells in vitro. Human Immunology, 1998, 59, 404-414.	1.2	11
246	Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Transplant Immunology, 1998, 6, 169-175.	0.6	6
247	Infant pediatric liver transplantation results equal those for older pediatric patients. Journal of Pediatric Surgery, 1998, 33, 20-23.	0.8	57
248	Primate renal transplants using immunotoxin. Surgery, 1998, 124, 438-447.	1.0	65
249	lmmunologic Risks of Combined Kidney–Pancreas Transplantation. Transplantation Proceedings, 1998, 30, 249-250.	0.3	6
250	Donor Factors Affecting Outcome After Pancreas Transplantation. Transplantation Proceedings, 1998, 30, 276-277.	0.3	61
251	Enteric Conversion of Bladder-Drained Pancreas Allografts: Experience in 95 Patients. Transplantation Proceedings, 1998, 30, 441-442.	0.3	23
252	Reversal of acute allograft rejection using immunotoxin. Transplantation Proceedings, 1998, 30, 2150-2151.	0.3	7

#	Article	IF	Citations
253	Living unrelated renal donation: The University of Wisconsin experience. Surgery, 1998, 124, 604-611.	1.0	79
254	PROCUREMENT, PRESERVATION, AND TRANSPORT OF CADAVER KIDNEYS. Surgical Clinics of North America, 1998, 78, 41-54.	0.5	33
255	Experience With 500 Simultaneous Pancreas-Kidney Transplants. Annals of Surgery, 1998, 228, 284-296.	2.1	275
256	ANALYSIS OF PRIMATE RENAL ALLOGRAFTS AFTER T-CELL DEPLETION WITH ANTI-CD3-CRM91,2. Transplantation, 1998, 66, 5-13.	0.5	49
257	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2. Transplantation, 1998, 66, 29-37.	0.5	273
258	POSTTRANSPLANT INFECTION IN ENTERIC VERSUS BLADDER-DRAINED SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1998, 66, 1746-1750.	0.5	96
259	A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION1. Transplantation, 1998, 66, 1751-1759.	0.5	72
260	Immunotoxins in organ transplantation. Current Opinion in Organ Transplantation, 1997, 2, 97.	0.8	0
261	CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8789-8794.	3.3	905
262	Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers. Human Gene Therapy, 1997, 8, 1763-1772.	1.4	186
263	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant International, 1997, 10, 152-156.	0.8	8
264	Emergency Portacaval Shunts: Is Orloff Correct?. HPB Surgery, 1997, 10, 253-265.	2.2	0
265	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant International, 1997, 10, 152-156.	0.8	20
266	Identification of new Mamu-DRB alleles using DGGE and direct sequencing. Immunogenetics, 1997, 45, 171-179.	1.2	69
267	Proceed with Caution: Liver Transplantation for Metastatic Neuroendocrine Tumors. Annals of Surgery, 1997, 225, 345-346.	2.1	19
268	FN18-CRM9 IMMUNOTOXIN PROMOTES TOLERANCE IN PRIMATE RENAL ALLOGRAFTS1. Transplantation, 1997, 63, 1-6.	0.5	196
269	SPLIT TOLERANCE INDUCED BY IMMUNOTOXIN IN A RHESUS KIDNEY ALLOGRAFT MODEL1. Transplantation, 1997, 63, 1339-1345.	0.5	50
270	Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. Surgery, 1996, 120, 719-724.	1.0	6

#	Article	IF	CITATIONS
271	Gene therapy in transplantation. Transplant Immunology, 1996, 4, 257-264.	0.6	19
272	Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. International Journal of Radiation Oncology Biology Physics, 1996, 34, 1055-1059.	0.4	11
273	Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney International, 1996, 49, 512-517.	2.6	56
274	THE INFLUENCE OF NATIVE NEPHRECTOMY ON THE INCIDENCE OF RECURRENT DISEASE FOLLOWING RENAL TRANSPLANTATION FOR PRIMARY GLOMERULONEPHRITIS1. Transplantation, 1996, 61, 228-234.	0.5	66
275	IMMUNOSUPPRESSIVE EFFECTS OF AN HLA CLASS I-DERIVED PEPTIDE IN A RAT CARDIAC ALLOGRAFT MODEL. Transplantation, 1996, 61, 1222-1228.	0.5	26
276	DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1. Transplantation, 1996, 61, 1581-1586.	0.5	153
277	ADENOVIRUS-MEDIATED GENE TRANSFER INTO RAT CARDIAC ALLOGRAFTS. Transplantation, 1996, 61, 1726-1729.	0.5	40
278	CLINICAL HEPATITIS AFTER TRANSPLANTATION OF HEPATITIS C VIRUS-POSITIVE KIDNEYS. Transplantation, 1996, 62, 1758-1762.	0.5	23
279	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 631-647.	0.5	91
280	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 631-633.	0.5	56
281	PRETRANSPLANT STATUS AND PATIENT SURVIVAL FOLLOWING LIVER TRANSPLANTATION. Transplantation, 1995, 60, 920-925.	0.5	10
282	Living Related and Unrelated Donors for Kidney Transplantation A 28-Year Experience. Annals of Surgery, 1995, 222, 353-364.	2.1	91
283	SUCCESSFUL EXTRARENAL TRANSPLANTATION FROM NON-HEART-BEATING DONORS. Transplantation, 1995, 59, 977-982.	0.5	190
284	Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery, 1995, 118, 615-620.	1.0	92
285	Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. Human Immunology, 1994, 40, 191-201.	1.2	50
286	Use of Donor Serum to Prevent Passive Transfer of Hyperacute Rejection. Journal of Surgical Research, 1994, 57, 150-155.	0.8	7
287	100 Consecutive liver transplants in infants and children: An 8-year experience. Journal of Pediatric Surgery, 1994, 29, 1135-1140.	0.8	35
288	INDUCTION OF SPECIFIC TOLERANCE BY INTRATHYMIC INJECTION OF RECIPIENT MUSCLE CELLS TRANSFECTED WITH DONOR CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX. Transplantation, 1994, 57, 990-996.	0.5	56

#	Article	IF	CITATIONS
289	Human interleubâ€⊋ and lymphoproliferative (Tâ€helper cell) responses to soluble HLA class I antigens <i>in vitro</i> : I. Specificity for polymorphic domains ^{1,2} . Tissue Antigens, 1993, 42, 35-38.	1.0	6
290	A Controlled, Double-Blind, Randomized Trial of Verapamil and Cyclosporine in Cadaver Renal Transplant Patients. American Journal of Kidney Diseases, 1993, 21, 189-195.	2.1	24
291	Urological Complications in 210 Consecutive Simultaneous Pancreas-Kidney Transplants with Bladder Drainage. Annals of Surgery, 1993, 218, 561-570.	2.1	116
292	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATION—A MULTIVARIATE ANALYSIS. Transplantation, 1993, 55, 807-813.	0.5	937
293	RETRANSPLANTATION OF THE LIVER—A SEVEN-YEAR EXPERIENCE. Transplantation, 1993, 55, 1083-1086.	0.5	110
294	The Use of UW Solution in Clinical Transplantation A 4-year Experience. Annals of Surgery, 1992, 215, 579-585.	2.1	104
295	THE EFFECT OF DONOR AGE, RECIPIENT AGE, AND HLA MATCH ON IMMUNOLOGIC GRAFT SURVIVAL IN CADAVER RENAL TRANSPLANT RECIPIENTS1. Transplantation, 1992, 53, 55-58.	0.5	71
296	THE INFLUENCE OF RS-61443 ON ANTIBODY-MEDIATED REJECTION. Transplantation, 1992, 53, 696.	0.5	22
297	Experience With 100 Consecutive Simultaneous Kidney-Pancreas Transplants With Bladder Drainage. Annals of Surgery, 1991, 214, 703-711.	2.1	96
298	THE PREDICTIVE VALUE OF DONOR LIVER BIOPSIES FOR THE DEVELOPMENT OF PRIMARY NONFUNCTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1991, 51, 157-163.	0.5	346
299	MULTIVARIATE ANALYSIS OF DONOR-SPECIFIC VERSUS RANDOM TRANSFUSION PROTOCOLS IN HAPLOIDENTICAL LIVING-RELATED TRANSPLANTS. Transplantation, 1991, 51, 382-384.	0.5	13
300	ORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER. Transplantation, 1991, 51, 431-432.	0.5	65
301	The Effect of TLI and Cyclosporine on Xenograft Survival. Transplantation, 1990, 50, 1082.	0.5	6
302	Pneumatosis Intestinalis. Annals of Surgery, 1990, 212, 160-165.	2.1	205
303	Irradiation for xenogeneic transplantation. Radiotherapy and Oncology, 1990, 18, 29-37.	0.3	5
304	Anomalous biliary ducts associated with duodenal atresia. Journal of Pediatric Surgery, 1990, 25, 1266-1269.	0.8	40
305	HEPATIC TRANSPLANTATION INTO SENSITIZED RECIPIENTS. Transplantation, 1987, 43, 8-12.	0.5	79
306	XENOGRAFT SURVIVAL IN TWO SPECIES COMBINATIONS USING TOTAL-LYMPHOID IRRADIATION AND CYCLOSPORINE. Transplantation, 1987, 43, 173-175.	0.5	55

STUART J KNECHTLE

#	Article	IF	CITATIONS
307	INFILTRATING CELL PHENOTYPES AND PATTERNS ASSOCIATED WITH HEPATIC ALLOGRAFT REJECTION OR ACCEPTANCE. Transplantation, 1987, 43, 169-172.	0.5	26
308	The influence of dose and dose rate of total lymphoid irradiation in the rat cardiac allograft model. Radiotherapy and Oncology, 1987, 9, 311-318.	0.3	15
309	$\hat{l}\pm 1$ -Adrenergic effects and liver regeneration. Hepatology, 1987, 7, 1189-1194.	3.6	184
310	Identification of bacterial antigens in circulating immune complexes of infective endocarditis Journal of Clinical Investigation, 1982, 70, 271-280.	3.9	37
311	Harnessing the B Cell Response in Kidney Transplantation $\hat{a} \in \text{Current State}$ and Future Directions. Frontiers in Immunology, 0, 13, .	2.2	5